丽珠集团：癫痫适应症II期首例受试者已于今年7月入组

Core Viewpoint - LIZHU Group (000513) announced the development of NS-041, a novel highly selective KCNQ2/3 agonist, which is currently the only drug in China conducting clinical research for both epilepsy and depression at this target [1] Group 1: Drug Development - NS-041 has entered Phase II clinical trials for epilepsy, with the first subject enrolled in July 2023 [1] - The IND application for the depression indication has recently been accepted [1] - The drug has been optimized at the molecular structure level to avoid safety issues seen in previous generation drugs targeting the same site, with no potential ocular toxicity risks identified [1] Group 2: Mechanism and Efficacy - NS-041 exhibits better target selectivity, lower off-target risks for related subtypes, and higher lipophilicity, facilitating its passage through the blood-brain barrier [1] - Currently, there are no marketed anti-epileptic drugs targeting the same site globally [1] - In classical acute and chronic depression models in mice, NS-041 demonstrated significant anti-depressant effects [1]